Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Autologous tumour infiltrating lymphocytes - Iovance Biotherapeutics

Next Previous
Drug Profile

Autologous tumour infiltrating lymphocytes - Iovance Biotherapeutics

Alternative Names: Autologous expanded tumour infiltrating lymphocytes - Iovance Biotherapeutics; LN 145; LN-145-S1; MDA Autologous TILs; MDA Autologous Tumor Infiltrating Lymphocytes; MDA-TIL; MDA-TILs; TIL LN-145

Latest Information Update: 07 Mar 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator National Cancer Institute (USA); National Institutes of Health (USA)
  • Developer Iovance Biotherapeutics; National Cancer Institute (USA); National Institutes of Health (USA); University of Texas M. D. Anderson Cancer Center; Yale University
  • Class Antineoplastics; Immunotherapies; Tumour infiltrating lymphocyte therapies
  • Mechanism of Action Immunologic cytotoxicity; Lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cervical cancer
  • New Molecular Entity No

Highest Development Phases

  • Phase III Non-small cell lung cancer
  • Phase II Adenocarcinoma; Cervical cancer; Colorectal cancer; Head and neck cancer; Malignant melanoma; Osteosarcoma; Ovarian cancer; Soft tissue sarcoma; Triple negative breast cancer

Most Recent Events

  • 04 Mar 2024 The US FDA lifts the partial clinical hold on the phase II IOV-LUN-202 trial for Non-small cell lung cancer
  • 22 Dec 2023 The US FDA placed a clinical hold on the phase II IOV-LUN-202 trial in response to a recently reported Grade 5 (fatal) serious adverse event potentially related to the non-myeloablative lymphodepletion pre-conditioning regimen
  • 30 Nov 2023 Updated efficacy data from a phase II IOV-LUN-202 trial in Non small cell lung cancer released by Iovance Biotherapeutics
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top